Evidence map›Paper›PMID 35804906›Full record

ArticleCancers2022

The Differential Clinical Impacts of Cachexia and Sarcopenia on the Prognosis of Advanced Pancreatic Cancer.

Ya-Chin Hou, Chien-Yu Chen, Chien-Jui Huang, Chih-Jung Wang, Ying-Jui Chao, Nai-Jung Chiang, Hao-Chen Wang, Hui-Ling Tung, Hsiao-Chun Liu, Yan-Shen Shan

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Cancer cachexia: molecular basis and therapeutic advances.Signal transduction and targeted therapy · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Diversity in chemotherapy-induced cachexia.American journal of physiology. Cell physiology · 2025
    Review
  9. Article
  10. Review
  11. Observational
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Ya-Chin HouInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
Chien-Yu ChenSchool of Medicine, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
Chien-Jui HuangDivision of Gastroenterology and Hepatology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.ORCID 0000-0002-5503-9266
Chih-Jung WangInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.ORCID 0000-0002-7625-2891
Ying-Jui ChaoDivision of General Surgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
Nai-Jung ChiangDepartment of Oncology, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Hao-Chen WangInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
Hui-Ling TungDivision of General Surgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
Hsiao-Chun LiuDepartment of Clinical Medical Research, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
Yan-Shen ShanInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.ORCID 0000-0002-2457-5189
National Cheng Kung University Hospital · TWNational Cheng Kung University · TWNational Yang Ming Chiao Tung University · TW

Funding

Ministry of Health and Welfare MOST 109-2321-B-006-011, MOST 110-2321-B-006-005MOHW110-TDU-B-212-144026, MOHW111-TDU-B-221-014015, and MOHW111-TDU-B-211-134003.Ministry of Science and Technology MOST 109-2321-B-006-011, MOST 110-2321-B-006-005, MOST 110-2745-B-006-001, MOST 110-2327-B-037-001, and MOST 110-2813-C-006-035-B.
6 · The paper itself

Abstract

Pancreatic cancer (PC) has the highest frequency of developing cancer cachexia (CC)-sarcopenia (SC) syndrome, which negatively influences patients' outcome, quality of life, and tolerance/response to treatments. However, the clinical impacts of CC, SC, and their associated factors on outcomes for advanced PC has yet to be fully investigated. A total of 232 patients were enrolled in this study for the retrospective review of their clinical information and the measurement of skeletal muscle areas at the third lumber vertebra by computed tomography scan to identify CC or SC. The association and concurrent occurrence of clinicopathological features in each patient, prevalence rates, and prognosis with the CC or SC were calculated. CC and SC were observed in 83.6% (

Indexed as

advanced stageagealbuminbody mass indexcancer cachexiahemoglobinpancreatic cancersarcopenia

Identifiers

PMID35804906
PMCPMC9264865
OpenAlexW4283589598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.